


ART 34 AMDT

10/049666
JC11 Rec'd PGT/PTO 15 FEB 2002

- 18 -


AMENDED CLAIMS

1. A pharmaceutical formulation comprising (i) a benzamide derivative represented by the formula (1):



(1)


wherein A represents a structure shown by any one of the formula (2):



(2)

or a pharmaceutically acceptable salt thereof, (ii) one or more than one selected from the group consisting of an organic acid salt, an amino compound and an inorganic basic substance, and (iii) one or more than one selected from the group consisting of an excipient, a disintegrant, a binder, a lubricant, a coating agent and a solvent.


2. A pharmaceutical formulation comprising (i) a benzamide derivative represented by the formula (1):



(1)


wherein A represents a structure shown by any one of the formula (2):

10049666-021502




or a pharmaceutically acceptable salt thereof, and (ii) one or more than one selected from the group consisting of D-mannitol, partially gelatinized starch, carboxymethylstarch sodium, hydroxypropyl cellulose, magnesium stearate, hydroxypropyl methylcellulose and dimethylacetamide.

3. A pharmaceutical formulation comprising (i) a benzamide derivative represented by the formula (1):



wherein A represents a structure shown by any one of the formula (2):




or a pharmaceutically acceptable salt thereof, wherein said benzamide derivative or pharmaceutically acceptable salt thereof is dissolved in propylene glycol.

4. The pharmaceutical formulation according to any one of claims 1 to 3 wherein said benzamide derivative is represented by the formula (3):

10049666-021502

ART 34 AMDT



(3)

5 5. The pharmaceutical formulation according to claims 1, 2 and 4 wherein said pharmaceutical formulation is a solid formulation.

6. The pharmaceutical formulation according to claims 1 to 4 wherein said pharmaceutical formulation is a liquid formulation.

10 7. The pharmaceutical formulation according to claims 1, 4 and 5 wherein said excipient is D-mannitol.

8. The pharmaceutical formulation according to any one of claims 1, 4, 5 and 7 wherein said disintegrant is one or more than one selected from the group consisting of partly pregelatinized starch, carmellose calcium, and carboxymethylstarch sodium.

15 9. The pharmaceutical formulation according to any one of claims 1, 4, 5, 7 and 8 wherein said binder is hydroxypropyl cellulose.

20 10. The pharmaceutical formulation according to claims 1, 4, 5 and 7 to 9 wherein said lubricant is one or more than one selected from magnesium stearate and talc.

25 11. The pharmaceutical formulation according to claims 1, 4, 5 and 7 to 10 wherein said coating agent is hydroxypropyl methylcellulose.

30 12. The pharmaceutical formulation according to claims 1, 4 and 6 wherein said solvent is one or more than one selected from the group consisting of propylene glycol, dimethylacetamide, and polyethylene glycol.

13. The pharmaceutical formulation according to claims 1 and 4 to 12 wherein said organic acid salt is

127 34 AND 7

- 21 -

one or more than one selected from the group consisting of monosodium fumarate, sodium alginate, sodium dehydroacetate, sodium erythorbate, and trisodium citrate.

5 14. The pharmaceutical formulation according to claims 1 and 4 to 13 wherein said amino compound is one or more than one selected from the group consisting of
10 tris(hydroxymethyl)aminomethane, monoethanolamine, diethanolamine, triethanolamine, diisopropanolamine, triisopropanolamine, dihydroxyaluminum aminoacetate, arginine, creatinine, sodium glutamate, glycine, L-arginine L-glutamate and carbachol.

15 15. The pharmaceutical formulation according to claims 1 and 4 to 14 wherein said inorganic basic substance is one or more than one selected from the group
20 consisting of sodium carbonate, potassium carbonate, ammonium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydroxide, disodium phosphate, and ammonia.


25 16. The pharmaceutical formulation according to claims 1, 2, 4, 5, 7 to 11 and 13 to 15 wherein the formulation is a solid formulation which comprises granules prepared by a dry granulation method.

 17. The pharmaceutical formulation according to claims 1 to 4, 6 and 12 to 15 wherein the formulation is a liquid formulation and pH is adjusted within the range of 4 to 12.

10049666-021502


CLAIMS

1. A pharmaceutical formulation comprising a benzamide derivative represented by the formula (1):



5

wherein A represents a structure shown by any one of the formula (2):




10

or a pharmaceutically acceptable salt thereof, and one or more than one additive selected from the group consisting of an excipient, a disintegrant, a binder, a lubricant, a coating agent and a solvent.

15

2. The pharmaceutical formulation according to claim 1 wherein said benzamide derivative is represented by the formula (3):



20

3. The pharmaceutical formulation according to claim 1 or 2 wherein said excipient is D-mannitol.

4. The pharmaceutical formulation according to any one of claims 1 to 3 wherein said disintegrant is one or

25

more than one selected from the group consisting of partly pregelatinized starch, carmellose calcium, and carboxymethylstarch sodium.

5 5. The pharmaceutical formulation according to any one of claims 1 to 4 wherein said binder is hydroxypropyl cellulose.

6. The pharmaceutical formulation according to any one of claims 1 to 5 wherein said lubricant is one or more than one selected from magnesium stearate and talc.

10 7. The pharmaceutical formulation according to any one of claims 1 to 6 wherein said coating agent is hydroxypropyl methylcellulose.

15 8. The pharmaceutical formulation according to any one of claims 1 to 7 wherein said solvent is one or more than one selected from the group consisting of propylene glycol, dimethylacetamide, and polyethylene glycol.

20 9. The pharmaceutical formulation according to any one of claims 1 to 8 wherein said formulation further comprises one or more than one selected from the group consisting of an organic acid salt, an amino compound, and an inorganic basic substance.

25 10. The pharmaceutical formulation according to any one of claims 1 to 9 wherein said organic acid salt is one or more than one selected from the group consisting of monosodium fumarate, sodium alginate, sodium dehydroacetate, sodium erythorbate, and trisodium citrate.

30 11. The pharmaceutical formulation according to any one of claims 1 to 9 wherein said amino compound is one or more than one selected from the group consisting of tris(hydroxymethyl)aminomethane, monoethanolamine, diethanolamine, triethanolamine, diisopropanolamine, triisopropanolamine, dihydroxyaluminum aminoacetate, arginine, creatinine, sodium glutamate, glycine, L-arginine L-glutamate and carbachol.

35 12. The pharmaceutical formulation according to any one of claims 1 to 9 wherein said inorganic basic

substance is one or more than one selected from the group consisting of sodium carbonate, potassium carbonate, ammonium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydroxide, disodium phosphate, and ammonia.

- 5
13. The pharmaceutical formulation according to any one of claims 1 to 12 wherein the formulation is a solid formulation which comprises granules prepared by a dry granulation method.
- 10
14. The pharmaceutical formulation according to any one of claims 1 to 13 wherein the formulation is a liquid formulation and pH is adjusted within the range of 4 to 12.